Please login to the form below

Not currently logged in
Email:
Password:

cystic fibrosis

This page shows the latest cystic fibrosis news and features for those working in and with pharma, biotech and healthcare.

Orkambi row: government now considering Crown Use licensing

Orkambi row: government now considering Crown Use licensing

MPs call for radical solutions as deadlock remains. Vertex is under renewed pressure to reach agreement with NHS England on its cystic fibrosis drug Orkambi, with a government minister yesterday warning ... Despite these measures, cystic fibrosis

Latest news

More from news
Approximately 28 fully matching, plus 103 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Luckily, that plan B was waiting in the wings: Kalydeco (ivacaftor), the first ever disease-modifying treatment for cystic fibrosis gained approval in 2012. ... As many commentators have pointed out, early research into the disease was only sustained

  • The Orkambi row explained The Orkambi row explained

    The Orkambi timeline. July 2012: Vertex’s Kalydeco, the first medicine to treat the underlying cause of cystic fibrosis, is approved in Europe. ... March 2019: Vertex, NHSE and NICE meet with Matt Hancock to recommence discussions on cystic fibrosis

  • The Orkambi blame game The Orkambi blame game

    The deadlock between pharma company Vertex and NHS England over cystic fibrosis drug Orkambi was played out in a parliamentary hearing in London on 7 March, when the company’s CEO

  • #OrkambiNow? #OrkambiNow?

    In the middle, of course, are the cystic fibrosis patients, many of them young children, and their families. ... The US company, based in Cambridge, Massachusetts is a pioneer of groundbreaking ‘precision medicine’ drugs against cystic fibrosis

  • Deal Watch October 2018

    Mylan has enhanced its respiratory portfolio with the acquisition of Novartis’s TOBI Podhaler and TOBI solution, both products for treating Pseudomonas aeruginosa infections in cystic fibrosis patients. ... Licensing &. research. collaboration. $550m.

More from intelligence
Approximately 4 fully matching, plus 24 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
Fearless Girl cover
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)...

Infographics